Details for Patent: 7,332,472

✉ Email this page to a colleague

Which drugs does patent 7,332,472 protect, and when does it expire?

Patent 7,332,472 protects LUPKYNIS and is included in one NDA.

This patent has one hundred and sixty-three patent family members in thirty-four countries.

Summary for Patent: 7,332,472

Title:	Cyclosporine analogue mixtures and their use as immunomodulating agents
Abstract:	The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISA.sub.TX247, and derivatives thereof. Mixtures of ISA.sub.TX247 isomers exhibit a combination of enhanced potency and reduced toxicity over the naturally occurring and presently known cyclosporins. ISA.sub.TX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. The ratio of isomers in a mixture may range from about 10 to 90 percent by weight of the (E)-isomer to about 90 to 10 percent by weight of the (Z)-isomer, based on the total weight of the mixture.
Inventor(s):	Naicker; Selvaraj (Edmonton, CA), Yatscoff; Randall W. (Edmonton, CA), Foster; Robert T. (Edmonton, CA)
Assignee:	Isotechnika Inc. (Edmonton, CA)
Application Number:	11/118,830
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound; Delivery; Dosage form;

Drugs Protected by US Patent 7,332,472

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Aurinia	LUPKYNIS	voclosporin	CAPSULE;ORAL	213716-001	Jan 22, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		TREATMENT OF PATIENTS WITH ACTIVE LUPUS NEPHRITIS	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 7,332,472

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	036852	⤷ Sign Up
Argentina	036853	⤷ Sign Up
Austria	332917	⤷ Sign Up
Austria	401339	⤷ Sign Up
Austria	425178	⤷ Sign Up
Austria	437629	⤷ Sign Up
Australia	2002331509	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.